Held G, Zeynalova S, Murawski N et al.: Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol 31:4115-4122, 2013;
Murawski N, Held G, Ziepert M et al. The role of radiotherapy and intrathecal prophylaxis in extralymphatic craniofacial diffuse large B-cell lymphoma. Blood 2013;under revision.
Pfreundschuh M, Muller C, Zeynalova S et al. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood 2013.
Zeynalova S, Ziepert M, Scholz M et al. Comparison and modelling of pegylated or unpegylated G-CSF schedules in CHOP-14 regimen of elderly patients with aggressive B-cell lymphoma. Ann Hematol 2013;92(12):1641-1652.
Horn H, Ziepert M, Becher C et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013;121(12):2253-2263.
Binder C, Ziepert M, Pfreundschuh M et al. CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial. Ann Hematol 2013;92(11):1521-1528.